Global Neuroendocrine Tumors Drug Forecast and Market Analysis to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Neuroendocrine neoplasms are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body. Well-differentiated neuroendocrine tumors (NETs), represent the majority of NENs, and poorly differentiated neuroendocrine carcinomas (NECs), representing only 10-20% of all NENs. 62-67% of NETs occur in the gastrointestinal (GI) tract, specifically in the small intestine, appendix, and large intestine. 22-27% of NETs occur in the lungs, the second most common location of NETs, with about 30% of lung NETs occurring in the bronchial system, so-called bronchopulmonary. Approximately 7% of NETs can develop in the pancreas and 3% in the thymus.

The market of neuroendocrine cancers is facing some unique dynamics beginning in 2021. The class of somatostatin analogs is so important in the treatment of NETs that it represents approximately 55% of the global market share. In total, ~80% of this market's value is under threat of generic competition. For this market to see true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products. With only five products in late-stage development, this is not the case and thus the market value is forecast to increase from $3.1B in 2020 to $3.4B in 2030, at a CAGR of 0.9% in the 8MM.

Companies Mentioned

• Blueprint Medicines
• Bristol Myers Squibb
• Camurus AB
• Exelixis Inc
• Hutchmed
• Ipsen Pharma
• ITM Isotopen Technologien Munchen
• Merck & Co
• Novartis
• Pfizer
• Progenics Pharmaceuticals
• Roche
• Shanghai Junshi Bioscience

Key Highlights

• The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to expansions of currently marketed therapies in new markets during the forecast period.
• The main barriers to growth in the 8MM are patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care.
• Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.
• The most important unmet needs in the ALL market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.

Key Questions Answered

• Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
• How has the introduction of Lutathera shaped the 2nd and 3rd lines of therapy? How will the competition fare?
• What is the expected future uptake of immune checkpoint inhibitors across the 8MM?

Key Topics Covered:

1. Neuroendocrine Tumors: Executive Summary

1.1 The Neuroendocrine Tumor Market Will Grow at a 0.9% CAGR During 2020-2030

1.2 Key Improvements in Existing Mechanisms of Action Form the Dominant Corporate and R&D Strategy in Neuroendocrine Tumors

1.3 Matching a Patient with the Most Appropriate Therapy Remains the Most Important Unmet Need in Neuroendocrine Tumors

1.4 Low Level of Innovation Across the Late-Stage Pipeline to Introduce Minimal Disruption in the Treatment Landscape

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/w9roa4